Anti CD19-BAFF chimeric antigen receptor T cell therapy - Yake Biotechnology
Alternative Names: CD19-BAFF Targeted CAR T-cells injection - Shanghai YaKe BiotechnologyLatest Information Update: 09 Apr 2024
At a glance
- Originator Yake Biotechnology
- Class Anti-inflammatories; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 04 Apr 2024 Zhejiang University in collaboration with Shanghai YaKe Biotechnology plans a phase 0 trial for Precursor cell lymphoblastic leukaemia lymphoma and B-cell lymphoma (Second-line therapy or greater) in China (IV) in April 2024 (NCT06346912)
- 04 Mar 2024 Preclinical trials in Autoimmune disorders in China (IV), prior to March 2024 (Yake Biotechnology pipeline, March 2024)
- 28 Feb 2024 Shanghai YaKe Biotechnology plans a phase 0 trial for Autoimmune disorder (IV) (NCT06279923; TXB2023023)